
Opinion|Videos|January 3, 2025
Patient Tolerability of Talquetamab and Use of IVIG
Panelists discuss how recent PET is reviewed with the patient, and there is evidence of near resolution of PET avid EMD lesions, though they will continue to monitor adenopathy – most suspicious for a reactive process. For patients treated with IVIG, the goal is to maintain a biological level of IgG at 400 mg/dL.
Advertisement
Episodes in this series

Video content above is prompted by the following:
- Please walk through the patient’s treatment course on talquetamab, including what issues you have seen and how they have been dealt with.
- How do physicians think differently about the use of IVIGs for patients treated with talquetamab?
Advertisement
Related to this article

A complete response letter was given to ivonescimab for patients with previously treated EGFR-mutated NSCLC.

Matthew Karr, DO, highlights advances in the CLL paradigm, current goals in researching CNS lymphoma, and other future directions in hematology/oncology.

Ralph V. Boccia, MD, FACP, discussed educating hospital teams and using tocilizumab to manage bispecific toxicities when patients need admission.

Martin Gleave, CM, MD, FRCSC, FACS, explained how the GUNS trial is using tumor genomics to guide neoadjuvant therapy in high-risk prostate cancer.

Daniel Y.C. Heng, MD, MPH, FRCPC, explained how subsequent therapy and durable responses may have shaped overall survival results in LITESPARK-011.

Ralph V. Boccia, MD, FACP, noted how designated hospitals and a 24/7 on-call team support emergencies during bispecific step-up dosing.

Arturo Loaiza-Bonilla, MD, MSEd, FACP, co-founder of Massive Bio and system-wide chief of hematology and oncology at St. Luke’s, explains how AI is matching patients to clinical trials, where the technology falls short, and why he left academia to build what oncology was missing.
Advertisement
Advertisement
Trending on CancerNetwork
1
Matching Neoadjuvant Therapy to Tumor Genomics in High-Risk Prostate Cancer
2
Partnering With Local Hospitals to Manage CRS and ICANS From Bispecific Antibodies
3
FDA Approves Perioperative Durvalumab/Enfortumab Vedotin in MIBC
4
Subsequent Therapy May Have Narrowed the Overall Survival Gap in LITESPARK-011
5


